OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
Latest acquisition is Reglera, leading consulting firm for med devices and human tissue products
Cynthia LaConte, the acquisitive CEO of Dohmen Group (Milwaukee) has struck again: its sixth acquisition in the past two years is Reglera (Wheat Ridge, CO), which provides a range of outsourcing services to device and tissue developers. From its base as a logistics service provider to manufacturers, and a consulting and benefit-management firm to insurers, the company has now expanded into medical affairs, orphan-drug distribution, pharmacovigilance and safety training, and medical communications. Now it is looking to apply those same skill sets to the med device world.
For its part, Reglera provides a range of outsourced services, including quality control and document management (both for regulatory submissions and commercial operations), product development consulting, adverse event reporting, contract manufacturing and fulfillment, among others. “With over 500 clients we’ve worked with, we’ve seen it all, from the physician-entrepreneur to the largest med-device manufacturers around,” says CEO Clay Anselmo.
“As personalized medicine becomes an increasingly viable healthcare model, traditional lines between pharma, bio, tissue and devices begin to blur. Expanding our medical device capability became the next logical step in our strategic plan to provide a holistic suite of support services to Life Science companies that are making the transition to therapeutic care companies,” said LaConte.
Like its new parent, Reglera shares a “conflict free” business philosophy, according to Anselmo: The company delivers its work on a fee-for-service basis, not taking ownership of the products and staying apart from financial incentives from buyers. Potential synergies with the rest of the Dohmen organization—such as handling product distribution through Dohmen’s DDN Pharmaceutical Logistics unit—remain to be worked out.